Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$425.57
5.681.35%
À la fermeture: -
$425.57
0.000.00%
Après les heures de négociation: Oct 31, 4:04 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Vertex Pharmaceuticals Inc a un objectif de cours consensus de $492.13, basé sur les évaluations des 27 analystes. Le plus élevé est de $575 attribué par Citigroup le octobre 2, 2025, et le plus bas est de $405 attribué par RBC Capital le août 5, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Morgan Stanley, JP Morgan et Citigroup le octobre 10, 2025, octobre 8, 2025 et octobre 2, 2025. Avec un objectif de cours moyen de $514.33 entre Morgan Stanley, JP Morgan et Citigroup, il y a une variation implicite de 20.86% upside pour Vertex Pharmaceuticals Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Morgan Stanley
JP Morgan
Citigroup
Leerink Partners
Evercore ISI Group
1calculé à partir des notes des analystes
Notes d'analystes pour Vertex Pharmaceuticals
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/10/2025 | 2.92% | Morgan Stanley | $439 → $438 | Maintains | Equal-Weight | |||
10/08/2025 | 24.54% | JP Morgan | $517 → $530 | Maintains | Overweight | |||
10/02/2025 | 35.11% | Citigroup | $550 → $575 | Maintains | Buy | |||
09/25/2025 | 7.15% | Leerink Partners | $458 → $456 | Upgrade | Market Perform → Outperform | |||
09/11/2025 | 11.62% | Evercore ISI Group | $510 → $475 | Maintains | Outperform | |||
09/03/2025 | — | Raymond James | — | Initiates | → Market Perform | |||
08/07/2025 | 29.24% | Citigroup | $575 → $550 | Maintains | Buy | |||
08/06/2025 | -3.42% | Canaccord Genuity | $424 → $411 | Maintains | Hold | |||
08/06/2025 | 28.3% | Guggenheim | $558 → $546 | Maintains | Buy | |||
08/06/2025 | 8.09% | Wells Fargo | $460 → $460 | Upgrade | Equal-Weight → Overweight | |||
08/05/2025 | 15.14% | Truist Securities | $520 → $490 | Maintains | Buy | |||
08/05/2025 | 2.92% | Scotiabank | $442 → $438 | Maintains | Sector Perform | |||
08/05/2025 | 24.54% | BMO Capital | $557 → $530 | Maintains | Outperform | |||
08/05/2025 | -4.83% | RBC Capital | $430 → $405 | Maintains | Sector Perform | |||
08/05/2025 | 29.94% | UBS | $582 → $553 | Maintains | Buy | |||
08/05/2025 | 6.92% | Stifel | $494 → $455 | Maintains | Hold | |||
08/05/2025 | 13.96% | Cantor Fitzgerald | $535 → $485 | Maintains | Overweight | |||
08/05/2025 | 3.16% | Morgan Stanley | $460 → $439 | Maintains | Equal-Weight | |||
08/05/2025 | 12.32% | HC Wainwright & Co. | $550 → $478 | Maintains | Buy | |||
07/14/2025 | 21.48% | JP Morgan | $515 → $517 | Maintains | Overweight | |||
06/23/2025 | 29.24% | HC Wainwright & Co. | $550 → $550 | Reiterates | Buy → Buy | |||
06/20/2025 | 8.09% | Morgan Stanley | $464 → $460 | Maintains | Equal-Weight | |||
06/17/2025 | -1.31% | RBC Capital | $423 → $420 | Maintains | Sector Perform | |||
05/06/2025 | -0.6% | RBC Capital | $420 → $423 | Maintains | Sector Perform | |||
05/06/2025 | 3.86% | Scotiabank | $450 → $442 | Maintains | Sector Perform | |||
05/06/2025 | 9.03% | Morgan Stanley | $462 → $464 | Maintains | Equal-Weight | |||
05/06/2025 | 21.01% | JP Morgan | $512 → $515 | Maintains | Overweight | |||
05/06/2025 | 25.71% | Cantor Fitzgerald | $535 → $535 | Reiterates | Overweight → Overweight | |||
05/06/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
05/06/2025 | 18.19% | Leerink Partners | $550 → $503 | Downgrade | Outperform → Market Perform | |||
04/22/2025 | 25.71% | Cantor Fitzgerald | → $535 | Assumes | → Overweight | |||
04/01/2025 | -1.31% | RBC Capital | $408 → $420 | Maintains | Sector Perform | |||
03/31/2025 | 33.23% | B of A Securities | $555 → $567 | Maintains | Buy | |||
02/20/2025 | -4.13% | RBC Capital | $407 → $408 | Maintains | Sector Perform | |||
02/12/2025 | -0.37% | Canaccord Genuity | $408 → $424 | Upgrade | Sell → Hold | |||
02/11/2025 | 36.99% | UBS | $586 → $583 | Maintains | Buy | |||
02/11/2025 | 30.41% | B of A Securities | $540 → $555 | Maintains | Buy | |||
02/11/2025 | 22.19% | Truist Securities | $460 → $520 | Maintains | Buy | |||
02/11/2025 | -4.36% | RBC Capital | $402 → $407 | Maintains | Sector Perform | |||
02/11/2025 | 5.74% | Scotiabank | $433 → $450 | Maintains | Sector Perform | |||
02/11/2025 | 12.79% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
02/11/2025 | 9.74% | Barclays | $435 → $467 | Maintains | Equal-Weight | |||
02/11/2025 | 29.24% | HC Wainwright & Co. | $550 → $550 | Reiterates | Buy → Buy | |||
02/11/2025 | 7.86% | Morgan Stanley | $450 → $459 | Maintains | Equal-Weight | |||
02/11/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/04/2025 | 26.89% | B of A Securities | $522 → $540 | Maintains | Buy | |||
01/31/2025 | 2.22% | Barclays | $418 → $435 | Maintains | Equal-Weight | |||
01/31/2025 | 28.06% | BMO Capital | $520 → $545 | Maintains | Outperform | |||
01/31/2025 | 12.79% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
01/31/2025 | 1.75% | Scotiabank | $430 → $433 | Maintains | Sector Perform | |||
01/31/2025 | 29.24% | HC Wainwright & Co. | $535 → $550 | Maintains | Buy | |||
01/31/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
01/30/2025 | 8.09% | Wells Fargo | $460 → $460 | Downgrade | Overweight → Equal-Weight | |||
01/27/2025 | 25.24% | Piper Sandler | $535 → $533 | Maintains | Overweight | |||
01/24/2025 | 12.79% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
01/10/2025 | 7.15% | Morgan Stanley | $476 → $456 | Maintains | Equal-Weight | |||
01/10/2025 | 8.09% | Wells Fargo | $555 → $460 | Maintains | Overweight | |||
12/23/2024 | 8.09% | Truist Securities | $550 → $460 | Maintains | Buy | |||
12/23/2024 | 1.04% | Scotiabank | $426 → $430 | Maintains | Sector Perform | |||
12/23/2024 | 17.49% | JP Morgan | $503 → $500 | Maintains | Overweight | |||
12/20/2024 | -6.01% | RBC Capital | $451 → $400 | Maintains | Sector Perform | |||
12/20/2024 | -1.78% | Barclays | $509 → $418 | Maintains | Equal-Weight | |||
12/20/2024 | 22.19% | BMO Capital | $566 → $520 | Maintains | Outperform | |||
12/20/2024 | — | Needham | — | Reiterates | Hold → Hold | |||
12/20/2024 | 25.71% | HC Wainwright & Co. | $600 → $535 | Maintains | Buy | |||
12/19/2024 | — | Oppenheimer | — | Downgrade | Outperform → Perform | |||
12/19/2024 | 22.66% | B of A Securities | $545 → $522 | Maintains | Buy | |||
12/16/2024 | 16.08% | Stifel | $490 → $494 | Maintains | Hold | |||
12/09/2024 | 29.24% | Jefferies | $500 → $550 | Upgrade | Hold → Buy | |||
11/14/2024 | 35.11% | Citigroup | → $575 | Initiates | → Buy | |||
11/06/2024 | -4.13% | Canaccord Genuity | $361 → $408 | Maintains | Sell | |||
11/05/2024 | 14.2% | Scotiabank | $480 → $486 | Maintains | Sector Perform | |||
11/05/2024 | 37.7% | UBS | $562 → $586 | Maintains | Buy | |||
11/05/2024 | 12.79% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
11/05/2024 | 5.98% | RBC Capital | $437 → $451 | Maintains | Sector Perform | |||
11/05/2024 | 18.19% | JP Morgan | $510 → $503 | Maintains | Overweight | |||
11/05/2024 | 11.85% | Morgan Stanley | $473 → $476 | Maintains | Equal-Weight | |||
10/30/2024 | 26.89% | Oppenheimer | $550 → $540 | Maintains | Outperform | |||
10/21/2024 | 40.99% | HC Wainwright & Co. | $600 → $600 | Reiterates | Buy → Buy | |||
10/17/2024 | 32.06% | UBS | $477 → $562 | Maintains | Buy | |||
10/16/2024 | 12.79% | Scotiabank | → $480 | Initiates | → Sector Perform | |||
10/14/2024 | 27.12% | B of A Securities | $550 → $541 | Maintains | Buy | |||
10/10/2024 | — | Raymond James | — | Reinstates | → Market Perform | |||
10/09/2024 | 2.69% | RBC Capital | $425 → $437 | Maintains | Sector Perform | |||
10/08/2024 | 12.79% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
10/04/2024 | -0.13% | RBC Capital | $431 → $425 | Maintains | Sector Perform | |||
10/01/2024 | 11.38% | Morgan Stanley | $462 → $474 | Maintains | Equal-Weight | |||
09/19/2024 | 1.28% | RBC Capital | $431 → $431 | Reiterates | Sector Perform → Sector Perform | |||
08/05/2024 | 40.99% | HC Wainwright & Co. | $500 → $600 | Maintains | Buy | |||
08/05/2024 | 29.24% | Oppenheimer | $500 → $550 | Maintains | Outperform | |||
08/05/2024 | 19.84% | JP Morgan | $505 → $510 | Maintains | Overweight | |||
08/05/2024 | 29.24% | Truist Securities | $508 → $550 | Reiterates | Buy → Buy | |||
08/05/2024 | 19.6% | Barclays | $472 → $509 | Downgrade | Overweight → Equal-Weight | |||
08/02/2024 | 21.01% | Evercore ISI Group | $438 → $515 | Maintains | Outperform | |||
08/02/2024 | 31.12% | Guggenheim | $450 → $558 | Maintains | Buy | |||
08/02/2024 | 12.79% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
08/02/2024 | 25.71% | Piper Sandler | $500 → $535 | Maintains | Overweight | |||
07/31/2024 | -11.65% | Canaccord Genuity | $371 → $376 | Maintains | Sell | |||
07/26/2024 | — | Needham | — | Reiterates | → Hold | |||
07/23/2024 | 17.49% | TD Cowen | $450 → $500 | Maintains | Buy |
FAQ
Quel est le cours indicatif de l'action Vertex Pharmaceuticals (VRTX) ?
Le dernier objectif de prix pour Vertex Pharmaceuticals (NASDAQ:VRTX) a été rapporté par Morgan Stanley le octobre 10, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $438.00 s'attendant à ce que VRTX se rise dans les 12 prochains mois (un possible changement de 2.92% upside). 77 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Vertex Pharmaceuticals (VRTX) ?
La dernière note d'analyste pour Vertex Pharmaceuticals (NASDAQ:VRTX) a été fournie par Morgan Stanley, et Vertex Pharmaceuticals maintenu leur note equal-weight.
Quand a eu lieu la dernière mise à niveau pour Vertex Pharmaceuticals (VRTX) ?
La dernière amélioration pour Vertex Pharmaceuticals Inc a eu lieu le septembre 25, 2025 lorsque Leerink Partners a augmenté leur objectif de prix à $456. Leerink Partners avait précédemment a market perform pour Vertex Pharmaceuticals Inc.
Quand a eu lieu la dernière dégradation pour Vertex Pharmaceuticals (VRTX) ?
La dernière réduction pour Vertex Pharmaceuticals Inc a eu lieu le mai 6, 2025 lorsque Leerink Partners a changé leur objectif de prix de $550 à $503 pour Vertex Pharmaceuticals Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Vertex Pharmaceuticals (VRTX) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Vertex Pharmaceuticals, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Vertex Pharmaceuticals a été déposée le octobre 10, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 10, 2026.
La note d'analyste pour Vertex Pharmaceuticals (VRTX) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Vertex Pharmaceuticals (VRTX) était un maintenu avec un objectif de prix de $439.00 à $438.00. Le prix actuel de Vertex Pharmaceuticals (VRTX) est de $425.57, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.